Trending Up0.0118 (2.0405%)
  • Bid / Lots
    0.5900/ 2
  • Ask / Lots
    0.6000/ 1
  • Open / Previous Close
    0.6090 / 0.5783
  • Day Range
    Low 0.5801
    High 0.6332
  • 52 Week Range
    Low 0.3750
    High 3.4000
  • Volume
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.5783
09:32 ET1610.609
09:39 ET1790.61
09:42 ET1000.61
09:44 ET11080.600001
09:51 ET12840.599999
10:08 ET2250.5801
10:27 ET1000.5803
10:31 ET30000.580201
10:38 ET116000.5802
10:54 ET2000.6001
10:56 ET2000.5868
11:00 ET1000.619899
11:03 ET7500.6185
11:12 ET1700.599349
11:27 ET10000.5991
11:30 ET33000.5802
11:48 ET241960.5806
11:50 ET353120.581
11:54 ET9000.5995
11:56 ET1000.5995
11:57 ET9000.5995
11:59 ET4000.604
12:01 ET106000.604
12:03 ET7000.6
12:06 ET2000.604
12:08 ET30190.6
12:10 ET2000.6
12:15 ET54550.618
12:17 ET76000.6176
12:19 ET1000.604
12:21 ET76000.5997
12:26 ET2000.608
12:28 ET1000.6047
12:33 ET10000.6042
12:35 ET10690.6177
12:44 ET15000.617899
12:53 ET3000.6078
01:02 ET5000.6044
01:06 ET1000.6078
01:09 ET1000.6078
01:24 ET7000.6078
01:26 ET1000.61
01:27 ET3480.6006
02:20 ET10000.6068
02:30 ET3000.5999
03:33 ET114400.6299
03:35 ET26000.6318
03:37 ET83910.6243
03:46 ET3500.615
03:48 ET1000.6196
03:57 ET43310.5901
04:00 ET5000.5901
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNLTX
Neoleukin Therapeutics Inc
United StatesRUBY
Rubius Therapeutics Inc
United StatesELEV
Elevation Oncology Inc
United StatesCMMB
Chemomab Therapeutics Ltd
United StatesCHEK
Check Cap Ltd
United StatesAMTI
Applied Molecular Transport Inc.
As of 2023-02-04

Company Information

Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. The Company's lead product candidate, NL-201, is an interleukin-2 (IL-2)/ interleukin-15 (IL-15) immunotherapy designed to eliminate binding to the alpha subunit of the IL-2 receptor (also known as CD25) while enhancing binding to the beta and gamma subunits. NL-201 is designed to mimic the therapeutic activity of the cytokines IL-2 and IL-15 for the treatment of various types of cancer, including renal cell carcinoma (RCC), melanoma and hematological malignancies. Its Neoleukin platform uses a set of advanced computational algorithms and methods to design functional de novo proteins. NL-201 holds promise in combination with cell therapy to expand and maintain populations of transplanted CAR-T and natural killer (NK) cells.

Contact Information

1616 Eastlake Ave E Ste 360SEATTLE, WA, United States 98102-3795


Independent Chairman of the Board
Todd Simpson
President, Chief Executive Officer, Principal Financial Officer, Director
Jonathan Drachman
Senior Vice President Legal, General Counsel
Donna Cochener
Senior Vice President - Corporate Development
Carl Walkey
Vice President, Head of Research
Bill Arthur

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.